CSIMarket
 
Purple Biotech Ltd   (PPBT)
Other Ticker:  
 
 
Price: $0.7249 $0.03 4.257%
Day's High: $0.75 Week Perf: -5.55 %
Day's Low: $ 0.69 30 Day Perf: -4 %
Volume (M): 53 52 Wk High: $ 2.16
Volume (M$): $ 38 52 Wk Avg: $1.25
Open: $0.70 52 Wk Low: $0.53



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 22
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Purple Biotech Ltd
Purple Biotech Ltd is a biotechnology company that focuses on developing innovative therapies for a range of medical conditions. The company's primary goal is to harness the power of cellular therapies to address various diseases and improve patient outcomes. Purple Biotech is known for its cutting-edge research and development efforts to create personalized medicine and targeted therapies. With a dedicated team of scientists and medical professionals, the company aims to bring groundbreaking advancements to the field of biotechnology and make a positive impact on patients' lives.


   Company Address: 4 Oppenheimer Street Rehovot 7670104
   Company Phone Number: 3-933-3121   Stock Exchange / Ticker: NASDAQ PPBT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Purple Biotech Achieves Promising Milestone, Establishes Recommended Phase 2 Dose for Breakthrough Head and Neck Cancer Treatment - NT219

Published Thu, Feb 1 2024 12:30 PM UTC

Purple Biotech Advances NT219 in the Treatment of Head and Neck Cancer, Reaching Recommended Phase 2 DoseREHOVOT, Israel, Feb. 01, 2024 - Purple Biotech Ltd. (Purple Biotech or the Company) (NASDAQ/TASE: PPBT), a pioneer in developing groundbreaking therapies that target the tumor microenvironment, has recently achieved a significant milestone in the treatment of head and ne...

Shares

Purple Biotech Takes a Bold Leap Forward: $5 Million Offering Paves the Way for Game-Changing Cancer Therapies

Published Tue, Oct 17 2023 12:00 PM UTC

Purple Biotech Announces $5 Million Registered Direct Offering: A Boost for Innovative Cancer Therapies
In an exciting development, Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biotech company focusing on novel therapies combating tumor immune evasion and drug resistance, has announced a registered direct offering. The offering involves the purchase and sale...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com